Live Analyst Rating Changes 1511 upgrades, downgrades & price-target moves · freshest Wall Street data, updated daily View live feed →
Analyst Tracker/Faisal Khurshid
JEF
Faisal Khurshid
Wall Street Analyst
★★★★☆
#466
on 13Foresight · ranked by our own returns
54%
Success Rate
+34.8%
Average Return
19 of 35 calls profitable · +24.0% vs benchmark
📈 Across the calls we could measure, roughly 54% of Faisal Khurshid's ratings turned a profit when each position was held for 1 year — averaging +34.8% per rating. These figures are computed by 13Foresight from historical prices, not supplied by the analyst.

Rating Distribution

75 Buy 20 Hold 0 Sell
Faisal's Stock Coverage 37 ratings · 2026-06-19
Company Date Position Consensus Price Target 1-Yr Return
ABVX
Abivax SA Sponsored ADR
Jun 01, 2026 HOLD Strong Buy
+20.7% avg upside
15 analysts
$90.00
9.21% Downside
-22.8%
PTCT
PTC Therapeutics
May 27, 2026 BUY Strong Buy
-1.4% avg upside
29 analysts
$85.00
7.62% Upside
+11.1%
ONC
BeOne Medicines
May 21, 2026 HOLD Strong Buy
+28.6% avg upside
28 analysts
$333.00
23.34% Upside
-15.2%
SMMT
Summit Therapeutics
May 21, 2026 HOLD Strong Buy
+112.6% avg upside
27 analysts
$17.00
23.65% Upside
-20.6%
ASND
Ascendis Pharma
May 06, 2026 BUY Strong Buy
+16.9% avg upside
24 analysts
$290.00
25.73% Upside
-5.3%
SNDX
Syndax Pharmaceuticals
May 01, 2026 BUY Strong Buy
+88.7% avg upside
27 analysts
$37.00
94.67% Upside
-4.1%
RVMD
Revolution Medicines
Apr 10, 2026 BUY Strong Buy
-12.2% avg upside
32 analysts
$140.00
14.11% Downside
+63.6%
VSTM
Verastem
Mar 30, 2026 BUY Strong Buy
+259.4% avg upside
23 analysts
$15.00
264.12% Upside
-17.5%
FDMT
4D Molecular Therapeutics
Mar 30, 2026 BUY Strong Buy
+266.1% avg upside
15 analysts
$21.00
117.35% Upside
+6.8%
VRDN
Viridian Therapeutics
Mar 30, 2026 BUY Strong Buy
+103.6% avg upside
32 analysts
$29.00
74.32% Upside
-13.1%
ANIP
ANI Pharmaceuticals
Mar 25, 2026 BUY Strong Buy
+28.6% avg upside
11 analysts
$120.00
50.99% Upside
+5.3%
INSM
Insmed
Mar 17, 2026 BUY Strong Buy
+82.1% avg upside
36 analysts
$228.00
138.04% Upside
-31.6%
COGT
Cogent Biosciences
Mar 16, 2026 BUY Strong Buy
+7.4% avg upside
26 analysts
$55.00
59.17% Upside
-4.1%
ALNY
Alnylam Pharma
Mar 15, 2026 HOLD Strong Buy
+23.4% avg upside
51 analysts
$330.00
18.60% Upside
-11.3%
INCY
Incyte
Mar 15, 2026 HOLD Buy
+1.0% avg upside
47 analysts
$94.00
4.28% Downside
+6.4%
IMTX
Immatics
Mar 15, 2026 BUY Strong Buy
+87.3% avg upside
15 analysts
$18.00
84.11% Upside
+10.8%
KYMR
Kymera Therapeutics
Mar 15, 2026 BUY Strong Buy
+9.0% avg upside
36 analysts
$110.00
21.66% Upside
+7.5%
IMCR
Immunocore Holdings
Mar 15, 2026 HOLD Strong Buy
+124.5% avg upside
22 analysts
$33.00
15.34% Upside
-8.2%
DSGN
Design Therapeutics
Mar 15, 2026 BUY Strong Buy
+45.3% avg upside
9 analysts
$15.00
20.51% Upside
+30.8%
CTNM
Contineum Therapeutics, Inc. Class A
Dec 15, 2025 BUY Strong Buy
+70.7% avg upside
8 analysts
$21.00
75.95% Upside
+10.6%
RYTM
Rhythm Pharmaceuticals
Dec 15, 2025 BUY Strong Buy
+25.2% avg upside
19 analysts
$142.00
46.62% Upside
-14.8%
ABCL
AbCellera Biologics
Nov 07, 2025 HOLD Strong Buy
+139.4% avg upside
15 analysts
$4.00
27.61% Downside
+12.8%
NRIX
Nurix Therapeutics
Oct 23, 2025 HOLD Strong Buy
+76.3% avg upside
26 analysts
$12.00
31.71% Downside
+69.1%
LKFT
Lakefront Biotherapeutics
Oct 22, 2025 BUY Hold
+272.9% avg upside
24 analysts
$40.00
41.29% Upside
·
MNKD
MannKind
Oct 10, 2025 BUY Buy
+78.6% avg upside
22 analysts
$9.00
128.38% Upside
-32.2%
ATYR
aTyr Pharma
Sep 30, 2025 HOLD Buy
+2016.8% avg upside
17 analysts
-27.9%
ZURA
Zura Bio
Sep 30, 2025 BUY Strong Buy
+289.3% avg upside
12 analysts
-18.8%
PRTCY
PureTech Health
Sep 30, 2025 BUY Strong Buy
+194.2% avg upside
3 analysts
·
TRVI
Trevi Therapeutics
Sep 29, 2025 BUY Strong Buy
+17.9% avg upside
16 analysts
+58.7%
IMUX
Immunic
Sep 25, 2025 BUY Strong Buy
+166.2% avg upside
21 analysts
+54.3%
PTGX
Protagonist Therapeutics
Sep 18, 2025 BUY Strong Buy
-22.1% avg upside
19 analysts
+79.3%
SYRE
Spyre Therapeutics
Sep 11, 2025 BUY Strong Buy
-15.4% avg upside
23 analysts
+415.9%
STTK
Shattuck Labs
Aug 18, 2025 BUY Strong Buy
+369.1% avg upside
14 analysts
$2.00
59.52% Downside
+324.5%
GERN
Geron
Aug 12, 2025 BUY Strong Buy
+240.0% avg upside
19 analysts
$3.00
138.00% Upside
+5.9%
IRWD
Ironwood Pharma
Aug 07, 2025 HOLD Hold
+235.8% avg upside
23 analysts
$1.00
71.85% Downside
+300.0%
PLRX
Pliant Therapeutics
Aug 07, 2025 HOLD Buy
+1820.7% avg upside
21 analysts
$2.00
72.37% Upside
-26.8%
FR:SAN
Sanofi
Jul 28, 2025 BUY Strong Buy
+33.0% avg upside
30 analysts
·
🔒 32 more ratings — with price targets, crowd consensus and our measured returns.
Free account unlocks every analyst's full coverage table.
Faisal Khurshid — Frequently Asked Questions
How accurate are Faisal Khurshid's stock ratings?
Based on the calls 13Foresight could measure, about 54% of Faisal's ratings were profitable over a one-year hold, with an average return of +34.8% per rating, or +24.0% versus the S&P 500. We score every analyst the same way, from historical prices.
How is Faisal ranked on 13Foresight?
Faisal Khurshid is currently ranked #466 with a 4-star rating. Our rank blends hit rate, average return versus the market, and how many calls we have to judge — so a long, consistent record outweighs a few lucky picks. It is our own calculation, updated daily.
Which stocks does Faisal cover?
Faisal most recently has ratings on ABVX, PTCT, ONC, SMMT, ASND, SNDX, RVMD, VSTM, FDMT, VRDN, ANIP, INSM and 25 more. See the full coverage table above for positions, price targets and our measured returns.
Where can I see other analyst ratings?
Browse the full analyst leaderboard to compare Wall Street analysts ranked by their measured performance, success rate and average return.

Disclaimer: 13Foresight compiles analyst ratings and price targets from publicly available sources. Performance metrics, rankings and star ratings shown here are calculated independently by 13Foresight from historical market prices and may differ from figures published elsewhere. This information may be incomplete, delayed or inaccurate, is provided for research and informational purposes only, and is not investment advice. The underlying ratings and opinions are those of the respective analysts and their firms; 13Foresight accepts no liability for any decisions made based on this data.